, ;where Wg is the number of CYP1A2 gene polymorphisms (main pathway biotransformation of chlorpromazine); Ai – change of speed biotransformation of chlorpromazine depending on the genotype for each polymorphic marker of the CYP1A2 gene. If change is defined as speed deviation biotransformation of chlorpromazine by 50 % and higher, replacement of the drug is recommended. If change is defined as deceleration of speed biotransformation of chlorpromazine less than by 50 %, dose reduction is recommended. At change, defined as speed acceleration biotransformation of chlorpromazine more than by 50 %, dose increase is recommended.;EFFECT: use of this method enables individual dose selection chlorpromazine, determining degree of manifestation of deviation of its speed biotransformation depending on the genotype for each polymorphic marker of the CYP1A2 gene.;1 cl, 1 tbl"/>
公开/公告号RU2695658C1
专利类型
公开/公告日2019-07-25
原文格式PDF
申请/专利号RU20180134291
发明设计人 ZASTROZHIN MIKHAIL SERGEEVICH (RU);SYCHEV DMITRIJ ALEKSEEVICH (RU);GRISHINA ELENA ANATOLEVNA (RU);BRYUN EVGENIJ ALEKSEEVICH (RU);
申请日2018-09-28
分类号A61K31/54;G01N33/48;C12Q1/6827;A61P25/18;
国家 RU
入库时间 2022-08-21 11:46:04